StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Revenues

<< Previous

Bullboard Posts

Next >>

Post by NoGambleNoFuturon Jan 25, 2021 12:11am

267 Views

Post# 32372990

Revenues

Hey guys, I've done some research about this company, but I have a question regarding its revenues, if someone can help me out.

Revenues 2020

Q1 2020: 11.3k
Q2 2020: 99.8k
Q3 2020: 1.4M (increase due to covid-19)

Note 1 of the financial statements says this:

"The Company’s lead product, ColonSentry®, is a blood test to determine an individual’s current risk for having colorectal cancer."

My question is the following: What is generating the revenues of 11.3k and 99.8k in Q1 and Q2? Is it the sale of their product, ColonSentry? I'm just trying to understand where these revenues are coming from. Thanks.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages